KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Payables (2016 - 2025)

Historic Payables for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $808.0 million.

  • Gilead Sciences' Payables fell 1052.05% to $808.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $808.0 million, marking a year-over-year decrease of 1052.05%. This contributed to the annual value of $833.0 million for FY2024, which is 5145.45% up from last year.
  • Latest data reveals that Gilead Sciences reported Payables of $808.0 million as of Q3 2025, which was down 1052.05% from $582.0 million recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Payables ranged from a high of $905.0 million in Q4 2022 and a low of $537.0 million during Q2 2024
  • For the 5-year period, Gilead Sciences' Payables averaged around $660.1 million, with its median value being $614.0 million (2022).
  • Its Payables has fluctuated over the past 5 years, first plummeted by 8374.08% in 2021, then soared by 5409.56% in 2024.
  • Quarter analysis of 5 years shows Gilead Sciences' Payables stood at $705.0 million in 2021, then increased by 28.37% to $905.0 million in 2022, then plummeted by 39.23% to $550.0 million in 2023, then skyrocketed by 51.45% to $833.0 million in 2024, then dropped by 3.0% to $808.0 million in 2025.
  • Its last three reported values are $808.0 million in Q3 2025, $582.0 million for Q2 2025, and $737.0 million during Q1 2025.